Kuritzkes Daniel R
Harvard Medical School, Boston, MA, USA.
Top HIV Med. 2007 Nov-Dec;15(5):150-4.
Recent data suggest that the prevalence of drug-resistant HIV in newly diagnosed patients may have leveled off at approximately 10% over the past several years. Further, there is some indication that the rates of emergence of resistance during long-term treatment have decreased in recent years with optimization of antiretroviral therapy. The importance of initial resistance testing is emphasized by findings indicating markedly increased risk of treatment failure in patients with resistance mutations at baseline. Genotypic and phenotypic testing are each associated with advantages and disadvantages in initial and subsequent resistance testing. Data on resistance patterns for new drugs and new drug classes are beginning to emerge. This article summarizes a presentation on HIV resistance made by Daniel R. Kuritzkes, MD, at an International AIDS Society-USA Continuing Medical Education course in San Francisco in May 2007.
近期数据表明，在过去几年中，新诊断患者中耐药性艾滋病毒的流行率可能已稳定在约10%。此外，有迹象表明，近年来随着抗逆转录病毒疗法的优化，长期治疗期间耐药性的出现率有所下降。基线时存在耐药性突变的患者治疗失败风险显著增加，这一发现强调了初始耐药性检测的重要性。在初始和后续耐药性检测中，基因检测和表型检测各有优缺点。关于新药和新药物类别的耐药模式的数据开始出现。本文总结了医学博士丹尼尔·R·库里茨克斯于2007年5月在旧金山举行的美国国际艾滋病协会继续医学教育课程上所作的关于艾滋病毒耐药性的报告。
